American Society of Hermatology (ASH)

Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results From a Phase 2 Study

Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Acalabrutinib Vs Idelalisib Plus Rituximab (Idr) Or Bendamustine Plus Rituximab (Br) In Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (Cll): Ascend Final Results

Cost-effectiveness of Acalabrutinib Monotherapy Compared With Chlorambucil plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Real World Longitudinal Analysis of Anemia Treatment Prescriptions in Non-Dialysis-Dependent Chronic Kidney Disease Patients, a CKDopps Study

AZD4320 is a novel and potent BCL-2/XL dual inhibitor in targeting aggressive mantle cell lymphoma

How Do Progression-Free Survival and Toxicity Risks Influence Oncologist and Patient Preferences for Novel Agents in Chronic Lymphocytic Leukemia?

A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) and Angioimmunoblastic T-cell Lymphoma (AITL) (NCI-9930)

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients With Relapsed/Refractory Multiple Myeloma

Pooled Efficacy and Cardiovascular Analysis of Roxadustat Compared with Placebo in Anemia Correction in Chronic Kidney Disease Patients Not On Dialysis

Pooled Efficacy and Cardiovascular Safety Results of Roxadustat Compared with Epoetin Alfa in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis

Roxadustat Lowers Risk of RBC Transfusion in Patients with Anemia of CKD

Treatment pathways of non-dialysis dependent CKD patients with anemia: A report from the DISCOVER CKD retrospective cohort

Roxadustat treatment corrects anemia to hemoglobin (Hb) values ≥10 g/dL in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD)

Roxadustat treatment results in consistent improvements in hemoglobin (Hb) compared with placebo: an analysis of 3 multinational randomized controlled trials (RCTs) in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD)

Hemoglobin (Hb) correction with roxadustat is associated with improved iron homeostasis in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD)

Roxadustat Increases Hemoglobin in Anemic Non-Dialysis-Dependent (NDD) Chronic Kidney Disease (CKD) Patients Independent of Inflammation

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels